Q2 and H1 2026 saw accelerated growth and profitability, led by strong Nubeqa® sales and Branded Products. Key R&D milestones were reached for ODM-212, and guidance for 2026 was raised. Orphan drug status and FDA approvals highlight ongoing innovation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.